DPP4 and diabetes mellitus: Dipeptidyl Peptidase-4 (DPP-4) inhibitors and Glucagon-like Peptide One (GLP-1) Receptor Agonists (GLP-1RAs) are both recommended by clinical guidelines for the glycemic management of patients with type 2 diabetes mellitus (T2DM) across the disease spectrum.